Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country

Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthropathy, ankylosing spondylitis, ulcerative co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezones-Holguin, Edward, Gamboa-Cardenas, Rocio Violeta, Sanchez-Felix, Gadwyn, Chávez-Corrales, José, Helguero-Santin, Luis Miguel, Laban Seminario, Luis Max, Burela-Prado, Paula Alejandra, Castro-Reyes, Maribel Marilu, Fiestas, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874174/
https://www.ncbi.nlm.nih.gov/pubmed/31798442
http://dx.doi.org/10.3389/fphar.2019.01010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874174/
https://www.ncbi.nlm.nih.gov/pubmed/31798442
http://dx.doi.org/10.3389/fphar.2019.01010

Ejemplares similares